Triple Negative Breast Cancer (TNBC): Possible Biomarkers and Treatments  

Oleh:

Sutiono, Dias Rima ; Shalannandia, Widad Aghnia

Jenis: Article from Journal - ilmiah nasional - tidak terakreditasi DIKTI
Dalam koleksi: Cermin Dunia Kedokteran vol. 44 no. 02 (Feb. 2017), page 114-116.
Topik: BRCA1-Like; EpCAM; ITB1; Prognostic Biomarker; Triple Negative Breast Cancer
Fulltext: C04 v44 n2 p114 kelik2017.pdf (98.51KB)

Ketersediaan

Perpustakaan FK Nomor Panggil: C04.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Triple negative breast cancer (TNBC) is one of the breast cancer subtypes, which account for around 15-20% of overall breast cancer cases. Women with Hispanic or African-American descent are having higher risk factor to develop this type of breast cancer, especially in their premenopausal period (under 40). This highly aggressive and poor prognosis type of breast cancer does not have several molecular receptors (estrogen receptor, progesterone receptor, and HER2 receptor). The absence of those receptors leads to its insensitivity to hormonal therapies, resulting in limited choice of therapy. Numerous studies have been conducted to discover other potential therapies. The clinical characteristic and other information regarding triple negative breast cancer will be discussed along with several potential prognostic biomarkers and treatments for this cancer.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali